Physician profile
John A Steuter
NPI 1770745218
$4,008.74
in general payments reported to CMS, 2019-2025
20 companies · $536 in 2025
The $536 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $28.31 · 2021: $68.59 · 2022: $572 · 2023: $617 · 2024: $1,630 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,806 · Travel and Lodging: $977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.05 |
| Travel and Lodging | $976.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,945.68 | 2019-2025 | Cardiomems, Mitraclip, Coroflow |
| Medtronic, INC. | $593.95 | 2021-2025 | Corevalve Evolut R, Onyx Frontier |
| Edwards Lifesciences Corporation | $307.28 | 2022-2023 | Sapien 3 Ultra Resilia |
| Medtronic Vascular, INC. | $278.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $197.05 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $155.03 | 2019-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $126.60 | 2022-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $93.28 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $57.64 | 2019-2022 | |
| Amgen INC. | $57.15 | 2019-2025 | Repatha |
| Chiesi USA, INC. | $45.54 | 2019 | |
| Pfizer INC. | $38.17 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $22.81 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.73 | 2022 | |
| Organogenesis INC. | $20.14 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $18.65 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.44 | 2025 | |
| Vifor Pharma, INC. | $11.46 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Steuter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.